Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis

PloS One
Ting YuanXin Wang

Abstract

Bortezomib is recently studied as a novel agent in indolent lymphoma. The optimal schedule of bortezomib used in indolent lymphoma is still uncertain. We did a systematic review and meta-analysis of the clinical trials comparing the efficacy and toxicity of the weekly and biweekly schedules of bortezomib in patients with indolent lymphoma. We searched Pubmed, Cochrane Library and Emabase from inception to July 29, 2016. The primary outcome was the overall response rate including the complete response rate and the partial response rate. The secondary outcomes were the proportions of patients in each group experiencing the adverse events including the neutropathy, fatigue, diarrhea, nausea and neutropenia. After final screening, six trials were considered eligible for analysis. The results showed that the overall response rate of biweekly schedule was higher than that of weekly schedule in indolent lymphoma (OR 1.691;95%CI 1.02-2.80). Furthermore, there were no significant differences between the two schedules of bortezomib for the main adverse events. The biweekly schedule of bortezomib was more effective than the weekly schedule in indolent lymphoma, with similar proportion of toxicities.

References

Feb 1, 1996·Controlled Clinical Trials·A R JadadH J McQuay
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andre GoyAlma M Rodriguez
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'ConnorAndrew D Zelenetz
Feb 19, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P Boyle, J Ferlay
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wade T SwensonBrian K Link
Oct 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard I FisherThomas P Miller
Jan 18, 2006·Blood Reviews·Vikas Aurora, Jane N Winter
Jul 25, 2009·British Journal of Haematology·John GerecitanoOwen A O'Connor
Sep 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sven de VosAnthony L Boral
Feb 25, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John GerecitanoOwen A O'Connor
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurie H SehnMichael Crump
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nathan FowlerBruce D Cheson
Jan 1, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Vincent RibragBertrand Coiffier
Nov 5, 2013·Blood Reviews·Lisa J Crawford, Alexandra E Irvine
Sep 30, 2014·Expert Opinion on Pharmacotherapy·Prithviraj BoseSteven Grant
Nov 12, 2014·Future Oncology·David Aguiar-BujandaUriel Bohn-Sarmiento
Feb 7, 2015·Cancer Treatment and Research·Athena KritharisAndrew M Evens
Mar 5, 2015·Journal of the National Comprehensive Cancer Network : JNCCN·Caron A Jacobson, Arnold S Freedman
May 7, 2015·Wiley Interdisciplinary Reviews. Systems Biology and Medicine·Jacob W MyersonVladimir R Muzykantov
Mar 19, 2016·Blood·Brad S Kahl, David T Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.